title: Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice.
abstract: The discovery of anaplastic lymphoma kinase (ALK) gene rearrangements and the development of tyrosine kinase inhibitors (TKI) that target them have achieved unprecedented success in the management of patients with ALK-positive non-small cell lung cancer (NSCLC). Despite the high efficacy of crizotinib, the first oral ALK TKI approved for the treatment of ALK-positive NSCLC, almost all patients inevitably develop acquired resistance, showing disease progression in the brain or in other parenchymal sites. Second- or third-generation ALK TKIs have shown to be active in crizotinib-pretreated or crizotinib-naïve ALK-positive patients, even in those with brain metastases. In this review, the current knowledge regarding ALK-positive NSCLC, focusing on the biology of the disease and the available therapeutic options are discussed.
authors: Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy.
authors: Antonio
authors: A
authors: Passaro
authors: Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy; Department of Medical Oncology, Division of Experimental Medicine, San Raffaele Scientific Institute, Milan, Italy.
authors: Chiara
authors: C
authors: Lazzari
authors: Oncology Institute Dr Rosell, Quiron-Dexeus University Hospital, Barcelona, Spain.
authors: Niki
authors: N
authors: Karachaliou
authors: Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy.
authors: Gianluca
authors: G
authors: Spitaleri
authors: Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy.
authors: Alessia
authors: A
authors: Pochesci
authors: Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy.
authors: Chiara
authors: C
authors: Catania
authors: Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.
authors: Rafael
authors: R
authors: Rosell
authors: Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy.
authors: Filippo
authors: F
authors: de Marinis
keywords: ALK; NSCLC; alectinib; brain metastases; brigatinib; ceritinib; crizotinib; lorlatinib